Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

23.0%

105 terminated/withdrawn out of 456 trials

Success Rate

64.3%

-22.3% vs industry average

Late-Stage Pipeline

16%

75 trials in Phase 3/4

Results Transparency

98%

186 of 189 completed trials have results

Key Signals

95 recruiting186 with results86 terminated19 withdrawn

Enrollment Performance

Analytics

Phase 2

181(41.4%)

Phase 1

174(39.8%)

Phase 3

72(16.5%)

Early Phase 1

4(0.9%)

N/A

3(0.7%)

Phase 4

3(0.7%)

437Total

Phase 2(181)

Phase 1(174)

Phase 3(72)

Early Phase 1(4)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (456)

Showing 20 of 456 trials

NCT06660355Phase 2Recruiting

Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

Role: collaborator

NCT06991101Phase 2Recruiting

Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

Role: collaborator

NCT07731789Phase 2Not Yet Recruiting

Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma

Role: collaborator

NCT06773195Phase 1Recruiting

A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis

Role: collaborator

NCT06959225Phase 3Active Not Recruiting

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)

Role: lead

NCT07424222Phase 1Recruiting

Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)

Role: collaborator

NCT02876302Phase 2Completed

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Role: collaborator

NCT06548360Phase 3Recruiting

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

Role: lead

NCT05836324Phase 1Recruiting

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Role: lead

NCT07213973Phase 2Recruiting

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

Role: lead

NCT07214779Phase 3Recruiting

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Role: lead

NCT06855498Phase 3Recruiting

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Role: lead

NCT07284849Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Role: lead

NCT07522073Phase 3Recruiting

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

Role: lead

NCT06160791Phase 2Recruiting

Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

Role: collaborator

NCT06804811Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

Role: lead

NCT07441694Phase 1Recruiting

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

Role: lead

NCT07104565Phase 2Recruiting

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

Role: lead

NCT06179160Phase 1Recruiting

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Role: lead

NCT07008118Phase 1Recruiting

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

Role: lead